3 research outputs found
Prevalence of thyroid disorders among infertile women with menstrual irregularities
No full textBackground: The infertility problem is more common phenomenon among the women now a days and has increased over past 30 years. The present study was carried out to see the prevalence of thyroid disorders among infertile women with menstrual irregularities.Methods: It was a cross sectional study conducted at the Department of Obstetrics and Gynecology, Ibn Sina Medical College, Dhaka from January to December 2016. After taking informed consent, total 160 infertile women and 100 normal fertile women volunteers were selected on OPD basis between age group of 18-45 years. Out of 160 infertile women, 100 were of primary infertility and 60 of secondary infertility. Participants were selected on the basis of detailed history, clinical examination and laboratory investigations. Detailed history of participants including age, menstrual history, obstetric history, history of any medications were taken.Results: There was a higher prevalence of hypothyroidism in the infertile women as compared to the fertile one in the study group, particularly in secondary infertility. Oligomenorrhoea was most common in infertile women. Hypothyroidism is commonly associated with ovulatory failure. Hence, assessment of serum TSH is mandatory in the work up of all infertile women, especially those presenting with menstrual irregularities. So the basic approach should be to identify those hypothyroid individuals who have greatest risk for the development of infertility.Conclusion: Long standing hypothyroidism may develop ovulatory dysfunction. So identifying and treating hypothyroidism at an earlier stage before the appearance of ovulatory dysfunction can have potentially great preventive value.Bangladesh Crit Care J March 2018; 6(1): 22-25</jats:p
Unani preparation ‘Sharbat Misali’ is useful as an alternate medicine to safely treat anemia: A pilot study
No full textBackground: Unani Medicine had its golden past in the middle age. Allopathic medicine evolved with simultaneous exploration of modern scientific development. Discovery of chemicals and antibiotics to deal infectious disease led foundation of epitome of modern medicine. There is however growing tendency among people to show their to depend on plant source and time old preparations. It is estimated that about 80 percent of population of the Asia and African countries uses herbal medicine for health care. This scenario opened the scope and merit to evaluate the preparation(s) which people are still using and the present study tested the usefulness and safety of ‘Sarbat Misali’ an Unani hematinic preparation in treating anemia.Materials and Methods: A total 31 women of age 24-40 yrs were enrolled in the study following ethical guidelines. The volunteers offered the choice and were free to refuse for not being included. Anthropometry recorded and blood sample obtained for biochemical test from the consenting subjects and prescribed with the preparation. Weight recorded and blood samples taken at the baseline end of four weeks. During study period they were in touch for their allegiance to taking the test preparation. Hemoglobin was estimated using autoanalyzer. Serum creatinine and SGPT were determined by standard biochemical method using autoanalyzer.Results: Blood hemoglobin level showed significant increase at the end of the supplementation (12.03±0.82) compared to the baseline level (10.78±1.08) (p<0.001). Serum creatinine and SGOT did not show any statistical difference between before and after supplementation.Conclusion: Data concluded that Sharbat Misali an Unani preparation of hematinics improved hemoglobin level and safety was supported by the fact of unaltered hepatic and renal functional status, however, to conclusively comment on adverse and toxic effect(s) chronic study needs to be undertaken with attention of inclusion of exhaustive biochemical markers.Bangladesh Journal of Medical Science Vol.17(1) 2018 p.144-148</jats:p
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
No full textBACKGROUND: Post-partum haemorrhage is the leading cause of maternal death worldwide. Early administration of tranexamic acid reduces deaths due to bleeding in trauma patients. We aimed to assess the effects of early administration of tranexamic acid on death, hysterectomy, and other relevant outcomes in women with post-partum haemorrhage. METHODS: In this randomised, double-blind, placebo-controlled trial, we recruited women aged 16 years and older with a clinical diagnosis of post-partum haemorrhage after a vaginal birth or caesarean section from 193 hospitals in 21 countries. We randomly assigned women to receive either 1 g intravenous tranexamic acid or matching placebo in addition to usual care. If bleeding continued after 30 min, or stopped and restarted within 24 h of the first dose, a second dose of 1 g of tranexamic acid or placebo could be given. Patients were assigned by selection of a numbered treatment pack from a box containing eight numbered packs that were identical apart from the pack number. Participants, care givers, and those assessing outcomes were masked to allocation. We originally planned to enrol 15 000 women with a composite primary endpoint of death from all-causes or hysterectomy within 42 days of giving birth. However, during the trial it became apparent that the decision to conduct a hysterectomy was often made at the same time as randomisation. Although tranexamic acid could influence the risk of death in these cases, it could not affect the risk of hysterectomy. We therefore increased the sample size from 15 000 to 20 000 women in order to estimate the effect of tranexamic acid on the risk of death from post-partum haemorrhage. All analyses were done on an intention-to-treat basis. This trial is registered with ISRCTN76912190 (Dec 8, 2008); ClinicalTrials.gov, number NCT00872469; and PACTR201007000192283. FINDINGS: Between March, 2010, and April, 2016, 20 060 women were enrolled and randomly assigned to receive tranexamic acid (n=10 051) or placebo (n=10 009), of whom 10 036 and 9985, respectively, were included in the analysis. Death due to bleeding was significantly reduced in women given tranexamic acid (155 [1·5%] of 10 036 patients vs 191 [1·9%] of 9985 in the placebo group, risk ratio [RR] 0·81, 95% CI 0·65-1·00; p=0·045), especially in women given treatment within 3 h of giving birth (89 [1·2%] in the tranexamic acid group vs 127 [1·7%] in the placebo group, RR 0·69, 95% CI 0·52-0·91; p=0·008). All other causes of death did not differ significantly by group. Hysterectomy was not reduced with tranexamic acid (358 [3·6%] patients in the tranexamic acid group vs 351 [3·5%] in the placebo group, RR 1·02, 95% CI 0·88-1·07; p=0·84). The composite primary endpoint of death from all causes or hysterectomy was not reduced with tranexamic acid (534 [5·3%] deaths or hysterectomies in the tranexamic acid group vs 546 [5·5%] in the placebo group, RR 0·97, 95% CI 0·87-1·09; p=0·65). Adverse events (including thromboembolic events) did not differ significantly in the tranexamic acid versus placebo group. INTERPRETATION: Tranexamic acid reduces death due to bleeding in women with post-partum haemorrhage with no adverse effects. When used as a treatment for postpartum haemorrhage, tranexamic acid should be given as soon as possible after bleeding onset. FUNDING: London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation
